Scarica l'app Stockscreener
3.29
0.30%
-0.010
Pre-mercato:
3.32
0.03
+0.91%
Precedente Chiudi:
$3.30
Aprire:
$3.25
Volume 24 ore:
2.89M
Relative Volume:
0.61
Capitalizzazione di mercato:
$872.33M
Reddito:
$194.75M
Utile/perdita netta:
$-51.26M
Rapporto P/E:
-11.75
EPS:
-0.28
Flusso di cassa netto:
$-23.38M
1 W Prestazione:
+9.30%
1M Prestazione:
-17.13%
6M Prestazione:
+54.46%
1 anno Prestazione:
+143.70%
Intervallo 1D:
$3.24
$3.34
Intervallo di 1 settimana:
$3.03
$3.44
Portata 52W:
$1.24
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Nome
Akebia Therapeutics Inc
Settore
Telefono
617-871-2098
Indirizzo
245 FIRST STREET, CAMBRIDGE, MA
Confronta AKBA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
3.29 | 874.98M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
153.06 | 67.56B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.80 | 46.65B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.70 | 43.48B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.54 | 19.74B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
312.06 | 14.01B | 2.99B | 1.21B | 1.13B | 25.06 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-04 | Ripresa | H.C. Wainwright | Buy |
| 2025-04-28 | Iniziato | Leerink Partners | Outperform |
| 2025-04-01 | Iniziato | Jefferies | Buy |
| 2023-11-29 | Ripresa | BTIG Research | Buy |
| 2023-08-28 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-31 | Downgrade | Needham | Buy → Hold |
| 2022-03-31 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Reiterato | Needham | Buy |
| 2019-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-11 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-02 | Iniziato | JP Morgan | Overweight |
| 2019-03-20 | Iniziato | Citigroup | Neutral |
| 2018-09-07 | Ripresa | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Reiterato | Needham | Buy |
| 2018-06-06 | Reiterato | H.C. Wainwright | Buy |
| 2017-12-19 | Iniziato | Piper Jaffray | Overweight |
| 2017-12-07 | Iniziato | BTIG Research | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | Needham | Buy |
| 2016-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2016-12-20 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-11-15 | Iniziato | Aegis Capital | Buy |
| 2016-09-29 | Iniziato | Brean Capital | Buy |
| 2016-03-16 | Reiterato | Needham | Buy |
| 2016-01-21 | Iniziato | Credit Suisse | Neutral |
Mostra tutto
Akebia Therapeutics Inc Borsa (AKBA) Ultime notizie
Akebia Therapeutics Reports Record Revenue and Strategic Growth - The Globe and Mail
Akebia at Canaccord Conference: Strategic Growth in Anemia Treatment By Investing.com - Investing.com Canada
Does Akebia Therapeutics Inc. have declining or rising EPSVerified 200% Stock Tips - thegnnews.com
Is AKBA anticipated to rise today? - AInvest
The Akebia Therapeutics, Inc. (NASDAQ:AKBA) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - ca.finance.yahoo.com
Is Akebia Therapeutics (NASDAQ:AKBA) A Risky Investment? - simplywall.st
How moving averages guide Akebia Therapeutics Inc. tradingIntraday Signal Forecast for Fast Traders - Newser
Identifying reversal signals in Akebia Therapeutics Inc.Free Optimized Watchlist With Daily Adjustments - Newser
What’s next for Akebia Therapeutics Inc. stock priceFree Growth Based Stock Signal Screener - Newser
Akebia outlines access to over 275,000 dialysis patients for Vafseo in Q4 as DaVita pilot launches - MSN
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q2 2025 Earnings Call Transcript - Insider Monkey
Akebia Therapeutics Second Quarter 2025 Earnings: EPS: US$0.001 (vs US$0.041 loss in 2Q 2024) - Yahoo Finance
Akebia Therapeutics Inc. stock trend outlook and recovery pathAsset Growth Pattern and Return Summary - Newser
Akebia Therapeutics (AKBA) Gets a Buy from H.C. Wainwright - The Globe and Mail
What does recent volatility data suggest for Akebia Therapeutics Inc.Free Oversold Bounce Stock Play Ideas - Newser
Akebia Therapeutics Reports Strong Q2 2025 Growth - The Globe and Mail
Using Bollinger Bands to evaluate Akebia Therapeutics Inc.Trend Following Ideas with Volume Confirmation - Newser
Is Akebia Therapeutics Inc. reversing from oversold territoryFree Real Profit Trade Plan Suggestions - Newser
Akebia Therapeutics (AKBA.O) Surges 9.14% — No Technical Signals Fired, But Why? - AInvest
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Average Rating of “Buy” by Analysts - Defense World
Akebia (AKBA) Prepares for Q2 Earnings Announcement - GuruFocus
Akebia Therapeutics Inc (AKBA) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic ... By GuruFocus - Investing.com Canada
Akebia Therapeutics Inc (AKBA) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic Growth Initiatives - GuruFocus
Akebia Reports Q2 Vafseo Revenue Growth, Sets Sights on Expanding Access to 275,000 Dialysis Patients - AInvest
Akebia's Q2 2025 Earnings Call: Unpacking Contradictions in Vafseo Trends, Auryxia Revenue, and FDA Strategies - AInvest
Akebia (AKBA) Q2 Revenue Jumps 43% - AOL.com
Akebia Therapeutics shares rise 1.66% after-hours after Q2 revenue beat expectations and Vafseo growth. - AInvest
Akebia Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Akebia Therapeutics Inc (AKBA) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
Earnings call transcript: Akebia Ther Q2 2025 earnings miss, stock drops By Investing.com - Investing.com Canada
Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q2 - Yahoo Finance
Akebia Therapeutics, Inc. SEC 10-Q Report - TradingView
Akebia Therapeutics Q2 revenue smashes expectations - MarketScreener
Akebia Therapeutics Inc Q2 2025 Earnings: Revenue Surges to $62. - GuruFocus
Akebia reports Q2 EPS 0c vs (4c) last year - TipRanks
Akebia Q2 2025: Vafseo net product revenues at $13.3mln, total $60.5mln. - AInvest
Akebia Therapeutics to Present at Canaccord Genuity’s 45th Annual Growth Conference - GlobeNewswire
Akebia Q2 2025 Earnings Preview - MSN
Akebia Therapeutics CEO to Discuss Kidney Disease Innovations at Major Growth Conference - Stock Titan
Chart based exit strategy for Akebia Therapeutics Inc.Market Downturn Defense Strategy Analysis - Newser
Akebia Therapeutics Inc expected to post a loss of 2 cents a shareEarnings Preview - TradingView
Akebia Therapeutics (AKBA) Grants Stock Options to New Employees - MSN
Leerink Partners Reiterates a Buy Rating on Akebia Therapeutics (AKBA) With a $7 PT - MSN
Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization - GlobeNewswire
Price momentum metrics for Akebia Therapeutics Inc. explainedFree Alpha Focused Technical Trade Signals - Newser
Is it the right time to buy Akebia Therapeutics Inc. stockCapitalize on high-growth stocks early - Jammu Links News
What are the technical indicators suggesting about Akebia Therapeutics Inc.Invest confidently with real-time data analysis - Jammu Links News
What are analysts’ price targets for Akebia Therapeutics Inc. in the next 12 monthsInvest confidently with expert support - Jammu Links News
What institutional investors are buying Akebia Therapeutics Inc. stockBuild a portfolio that outperforms consistently - Jammu Links News
When is Akebia Therapeutics Inc. stock expected to show significant growthUnlock high-yield investment opportunities - Jammu Links News
Akebia Therapeutics Inc Azioni (AKBA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.29%
1.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):